JP2023547677A5 - - Google Patents

Info

Publication number
JP2023547677A5
JP2023547677A5 JP2023527081A JP2023527081A JP2023547677A5 JP 2023547677 A5 JP2023547677 A5 JP 2023547677A5 JP 2023527081 A JP2023527081 A JP 2023527081A JP 2023527081 A JP2023527081 A JP 2023527081A JP 2023547677 A5 JP2023547677 A5 JP 2023547677A5
Authority
JP
Japan
Prior art keywords
phage
propionibacterium acnes
recombinant
acne
dna vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023527081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547677A (ja
JP7904829B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/080675 external-priority patent/WO2022096596A1/en
Publication of JP2023547677A publication Critical patent/JP2023547677A/ja
Publication of JP2023547677A5 publication Critical patent/JP2023547677A5/ja
Application granted granted Critical
Publication of JP7904829B2 publication Critical patent/JP7904829B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023527081A 2020-11-04 2021-11-04 キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用 Active JP7904829B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063109832P 2020-11-04 2020-11-04
US202063109834P 2020-11-04 2020-11-04
US63/109,834 2020-11-04
US63/109,832 2020-11-04
US202163145969P 2021-02-04 2021-02-04
US202163145967P 2021-02-04 2021-02-04
US63/145,969 2021-02-04
US63/145,967 2021-02-04
PCT/EP2021/080675 WO2022096596A1 (en) 2020-11-04 2021-11-04 Cutibacterium acnes recombinant phages, method of production and uses thereof

Publications (3)

Publication Number Publication Date
JP2023547677A JP2023547677A (ja) 2023-11-13
JP2023547677A5 true JP2023547677A5 (enExample) 2024-11-06
JP7904829B2 JP7904829B2 (ja) 2026-08-13

Family

ID=78621842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023527079A Pending JP2023547676A (ja) 2020-11-04 2021-11-04 ＤＮＡペイロードをアクネ菌集団へとｉｎ ｓｉｔｕ送達するためのファージ由来粒子
JP2023527081A Active JP7904829B2 (ja) 2020-11-04 2021-11-04 キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023527079A Pending JP2023547676A (ja) 2020-11-04 2021-11-04 ＤＮＡペイロードをアクネ菌集団へとｉｎ ｓｉｔｕ送達するためのファージ由来粒子

Country Status (7)

Country Link
US (8) US11473093B2 (enExample)
EP (2) EP4240843A1 (enExample)
JP (2) JP2023547676A (enExample)
KR (2) KR20230117105A (enExample)
CA (2) CA3198876A1 (enExample)
IL (2) IL302448A (enExample)
WO (2) WO2022096596A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도
EP4337765A1 (en) * 2021-05-12 2024-03-20 Eligo Bioscience Production of lytic phages
US20260083787A1 (en) * 2022-09-06 2026-03-26 Trobix Bio Ltd. Systems for production of transducing particles, methods, kits, compositions and uses thereof
WO2025089839A1 (ko) * 2023-10-24 2025-05-01 중앙대학교 산학협력단 Crispr-cas 탑재 박테리오파지 및 이의 용도

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511769A (ja) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
JP2000508178A (ja) 1996-05-14 2000-07-04 スミスクライン・ビーチャム・コーポレイション 新規化合物
ATE348887T1 (de) 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
BR9813930A (pt) 1997-11-06 2006-12-19 Chiron Spa antìgeno neisserial
CA2310217A1 (en) 1997-11-26 1999-06-03 Bioresearch Ireland Extracellular matrix-binding proteins from staphylococcus aureus
ATE446368T1 (de) 1998-01-14 2009-11-15 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
WO1999053940A1 (en) 1998-04-23 1999-10-28 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
EP1144640A3 (en) 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
WO2000006737A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
EP2330192A1 (en) 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
IL141639A (en) 1998-08-31 2005-12-18 Inhibitex Inc Multicomponent vaccines
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2355364C (en) 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
CN1198932C (zh) 1999-03-26 2005-04-27 科特克斯(Om)有限公司 肺炎链球菌抗原
AU777856B2 (en) 1999-06-10 2004-11-04 Human Genome Sciences, Inc. Streptococcus pneumoniae proteins and vaccines
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
EP1268774A2 (en) 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
CA2407455A1 (en) 2000-04-27 2001-11-01 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US20040091495A1 (en) 2000-07-20 2004-05-13 Lars Bjorck Protein
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2426738A1 (en) 2000-10-26 2002-05-02 David William Holden Streptococcal genes
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
ATE557041T1 (de) 2001-05-18 2012-05-15 Us Gov Health & Human Serv Peptid-vakzinen gegen streptokokken der gruppe a
EP2339344A1 (en) 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
EP1412379B1 (en) 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2275127B1 (en) 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
RU2004135541A (ru) 2002-06-11 2005-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. (BE) Иммуногенные композиции
PT1551357E (pt) 2002-09-13 2014-10-10 Novartis Vaccines & Diagnostic Vacina contra os estreptococos do grupo b
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
CN1918176A (zh) 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
JP5127708B2 (ja) * 2005-07-12 2013-01-23 マイクレオス べスローテン フェンノートシャップ バクテリオファージ及びその使用
WO2007120362A2 (en) 2005-12-27 2007-10-25 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
WO2014165164A2 (en) 2013-03-12 2014-10-09 Albany Medical College Compositions and methods for treating autoimmune diseases
GB201600075D0 (en) * 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
JP2019509263A (ja) * 2016-02-05 2019-04-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の健康増進用組成物及び健康増進方法
EP3445844A4 (en) * 2016-04-21 2019-11-13 Naked Biome, Inc. SYNTHETIC BACTERIA AND METHODS OF USE
JP2019514419A (ja) * 2016-05-15 2019-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 座瘡を処置するための組成物及び方法
CA3084952A1 (en) * 2017-12-05 2019-06-13 Biomx Ltd. Bacteriophage treatment for acne and biofilms
CA3102353A1 (en) * 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도

Similar Documents

Publication Publication Date Title
JP2023547676A5 (enExample)
Deng et al. Advances in the T7 phage display system
Forterre Defining life: the virus viewpoint
CN103668472A (zh) 利用CRISPR/Cas9系统构建真核基因敲除文库的方法
JP2020511115A5 (enExample)
Sprygin et al. Capripoxviruses, leporipoxviruses, and orthopoxviruses: Occurrences of recombination
CN102703424B (zh) 一种重组工程介导的大肠杆菌基因组点突变的方法
JP2008533988A5 (enExample)
Zhang et al. Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain
KR20210046811A (ko) 락토바실러스 카제이 유래의 두 종류 프로모터를 이용한 두 가지 목적단백질의 동시 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법
CN105567718B (zh) 一种同时表达多个sgRNA的载体的构建方法
Sekhavati et al. Cloning, molecular analysis and epitopics prediction of a new chaperone GroEL Brucella melitensis antigen
US20190062379A1 (en) Mutant of L1 Protein of Human Papillomavirus Type 11
CN105859845A (zh) 绵羊肺炎支原体多表位融合抗原MO-meAg5及其制备方法和应用
Sharma et al. Advances and applications of molecular cloning in clinical microbiology
US9862933B2 (en) Method for in-vitro preparation of double-layered virus-like particles of rotavirus
EP3186361B1 (en) Enterococcus faecalis strains for the production of bacteriophage preparations
CN106636462A (zh) 检测巨细胞病毒ul54和ul97基因耐药突变的巢式pcr引物及方法
Datta Unlocking the power of molecular cloning: revolutionizing medical microbiology procedures
Yousefi et al. Cloning and molecular characterization of Omp31 gene from Brucella melitensis Rev 1 strain
Tahmoorespur et al. In silico analysis of Omp25 and BLS Brucella melitensis antigens for designing subunit vaccine
JP2004532011A (ja) 微生物病原体の生物学的に活性な構造体を同定する方法
Shmidov et al. An efficient, counter-selection-based method for prophage curing in Pseudomonas aeruginosa strains
Baclioglu et al. Cost effective filamentous phage based immunization nanoparticles displaying a full-length hepatitis B virus surface antigen
Wang et al. In Vivo Production of HN Protein Increases the Protection Rates of a Minicircle DNA Vaccine against Genotype VII Newcastle Disease Virus